Externalization of phosphatidylserine via multidrug resistance 1 (MDR1)/P-glycoprotein in oxalate-treated renal epithelial cells: implications for calcium oxalate urolithiasis
参考文献:1.Williamson P, Schlegel RA (2002) Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim Biophys Acta 1585(2–3):53–63PubMed CrossRef 2.Schroit AJ, Zwaal RF (1991) Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1071(3):313–329PubMed CrossRef 3.Contreras FX, Sanchez-Magraner L, Alonso A, Goni FM (2010) Transbilayer (flip–flop) lipid motion and lipid scrambling in membranes. FEBS Lett 584(9):1779–1786. doi:10.1016/j.febslet.2009.12.049 PubMed CrossRef 4.Devaux PF, Lopez-Montero I, Bryde S (2006) Proteins involved in lipid translocation in eukaryotic cells. Chem Phys Lipids 141(1–2):119–132. doi:10.1016/j.chemphyslip.2006.02.007 PubMed CrossRef 5.Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189(3):803–811. doi:10.1016/j.juro.2012.05.078 PubMed CrossRef 6.Tsujihata M (2008) Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol 15(2):115–120. doi:10.1111/j.1442-2042.2007.01953.x PubMed CrossRef 7.Thamilselvan S, Byer KJ, Hackett RL, Khan SR (2000) Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 164(1):224–229PubMed CrossRef 8.Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38(3):147–160. doi:10.1007/s00240-010-0271-8 PubMed PubMedCentral CrossRef 9.Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34(2):86–91. doi:10.1007/s00240-005-0016-2 PubMed CrossRef 10.Cao LC, Jonassen J, Honeyman TW, Scheid C (2001) Oxalate-induced redistribution of phosphatidylserine in renal epithelial cells: implications for kidney stone disease. Am J Nephrol 21(1):69–77. doi:10.1159/000046224 PubMed CrossRef 11.Wiessner JH, Hasegawa AT, Hung LY, Mandel NS (1999) Oxalate-induced exposure of phosphatidylserine on the surface of renal epithelial cells in culture. J Am Soc Nephrol (JASN) 10(Suppl 14):S441–S445 12.Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS (1997) Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol 272(1 Pt 2):F55–F62PubMed 13.Iida S, Ishimatsu M, Chikama S, Inoue M, Matsuoka K, Akasu T, Noda S, Khan SR (2003) Protective role of heparin/heparan sulfate on oxalate-induced changes in cell morphology and intracellular Ca2+. Urol Res 31(3):198–206. doi:10.1007/s00240-003-0317-2 PubMed CrossRef 14.Yu SL, Gan XG, Huang JM, Cao Y, Wang YQ, Pan SH, Ma LY, Teng YQ, An RH (2011) Oxalate impairs aminophospholipid translocase activity in renal epithelial cells via oxidative stress: implications for calcium oxalate urolithiasis. J Urol 186(3):1114–1120. doi:10.1016/j.juro.2011.04.106 PubMed CrossRef 15.Pohl A, Lage H, Muller P, Pomorski T, Herrmann A (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J 365(Pt 1):259–268. doi:10.1042/BJ20011880 PubMed PubMedCentral CrossRef 16.Sugawara S, Hosono M, Ogawa Y, Takayanagi M, Nitta K (2005) Catfish egg lectin causes rapid activation of multidrug resistance 1 P-glycoprotein as a lipid translocase. Biol Pharm Bull 28(3):434–441PubMed CrossRef 17.Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775(2):237–262. doi:10.1016/j.bbcan.2007.05.002 PubMed 18.Efferth T (2001) The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1(1):45–65PubMed CrossRef 19.Dean M, Hamon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42(7):1007–1017PubMed 20.Jonsson B, Nilsson K, Nygren P, Larsson R (1992) SDZ PSC-833—a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs 3(6):641–646PubMed CrossRef 21.van Den Elsen JM, Kuntz DA, Hoedemaeker FJ, Rose DR (1999) Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein. Proc Natl Acad Sci USA 96(24):13679–13684PubMedCentral CrossRef 22.Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84(1):265–269PubMed PubMedCentral CrossRef 23.Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115(10):2598–2608. doi:10.1172/JCI26662 PubMed PubMedCentral CrossRef 24.Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones. N Engl J Med 327(16):1141–1152. doi:10.1056/NEJM199210153271607 PubMed CrossRef 25.Sarica K, Erturhan S, Altay B (2007) Effect of verapamil on urinary stone-forming risk factors. Urol Res 35(1):23–27. doi:10.1007/s00240-006-0075-z PubMed CrossRef
作者单位:Yu-Hang Li (1) Shi-Liang Yu (1) Xiu-Guo Gan (1) Shang-Ha Pan (2) Yue-Qiu Teng (3) Rui-Hua An (1)
1. Department of Urology Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China 2. Department of Central Laboratory, First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China 3. Department of Central Laboratory of Blood Cancer, First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
刊物类别:Medicine
刊物主题:Medicine & Public Health Nephrology Urology and Andrology
出版者:Springer Netherlands
ISSN:1573-2584
文摘
Objectives We investigated the possible involvement of multidrug resistance protein 1 P-glycoprotein (MDR1 P-gp) in the oxalate-induced redistribution of phosphatidylserine in renal epithelial cell membranes.